International Psoriasis Council
Advancing Knowledge. Improving Care.
SESSION 1 – FRIDAY, NOVEMBER 15, 2019
9:00 am – 4:30 pm
Agenda
WELCOME + INTRODUCTION
SESSION TOPICS
Pathogenesis and how it relates to drug
Phenotypes and assessment of psoriasis and psoriatic arthritis
Pustular psoriasis
Comorbidities: Focus on metabolic syndrome and mental health
Optimizing the use of topicals and standard systemics
Optimizing the use of biologics
Challenging cases workshop: An integrated learning experience
Paradoxical reactions to biologics
Comprehensive management of psoriasis
CLOSING COMMENTS
SESSION 2 – SATURDAY, NOVEMBER 16, 2019
9:00 am – 1:00 pm
Agenda
WELCOME + INTRODUCTION
SESSION TOPICS
What did we learn? Reflections on challenging cases workshop from day 1
Challenging cases workshop – presented by delegates
Ambition in psoriasis – Striving for more
CLOSING COMMENTS
SESSION 1 – SATURDAY, JUNE 29, 2019
10:00 am – 6:00 pm
Agenda
REGISTRATION, PRE-TEST AND NETWORKING
OPENING COMMENTS
Novartis introduction and overview of program
Welcome and introduction to the International Psoriasis Council
PATHOPHYSIOLOGY OF PSORIASIS – ROLE OF CYTOKINES AND POTENTIAL TARGETS
Evolution of understanding of the cytokines; role of IL-13 and TNFi; differential role of IL-17
OVERVIEW OF PSORIASIS AND COMORBIDITIES
Epidemiology of plaque psoriasis
BREAK
THE CLINICAL SPECTRUM OF PSORIASIS
Screening and assessment, pros and cons and assessment tool, emphasis on PASI
TREATMENT GOALS
Evolution of management from PASI 75 to PASI 100
NON-BIOLOGIC SYSTEMIC AGENTS
Methotrexate, cyclosporine, apremilast and others
LUNCH
BIOLOGICS IN PSORIASIS
Anti-TNFs
IL 12/23
IL-17 and IL-23
MONITORING AND MAINTENANCE OF RESPONSE
Follow up of the patient; lab and clinical parameters
CHALLENGES IN THE LONG TERM MANAGEMENT OF PSORIASIS
Long term efficacy of biologics; reduction/loss of response over a period of time; how to approach such a patient and manag
BREAK
CHALLENGING CASES: IPC MASTERCLASS 1.0 EXPERIENCES
CLOSING COMMENTS
SESSION 1 – SUNDAY, JUNE 30, 2019
9:00 am – 3:00 pm
Agenda
BREAKFAST AND NETWORKING
COMPLEXITIES OF DIAGNOSIS AND TREATMENT – BREAK OUT SESSIONS
Assessment scoring
Treatment failures
Treatment guidelines
CHALLENGING CASES: PRESENTED BY THE FACULTY
Case 1: Palmoplantar
Case 2: Scalp
Case 3: Psoriasis with heart failure
BREAK
NEW TREATMENT PARADIGMS IN THE MANAGEMENT OF PSORIASIS
Role of PDE-4i and P19 as a target
TREATING BEYOND THE SKIN
Focus on psoriatic arthritis: Risk factors, screening and diagnosis
LUNCH
MANAGING COMORBIDITIES AND PSORIASIS IN SPECIAL POPULATIONS – BREAK OUT SESSIONS
Topic 1: Children
Topic 2: Women
Topic 3: Comorbidities
EVALUATION AND CLOSING
1ª MÓDU
Masterclass 2021 Programa: Actualizaciones en Psoriasis
Timezones:
Guatemala City/San Jose: 12:00 pm – 2:00 pm
Bogota/Mexico City: 1:00 pm – 3:00 pm
Santiago/Asunción: 2:00 pm – 4:00 pm
Buenos Aires/São Paulo: 3:00 pm – 5:00 pm
Agenda
Introducciones
Claudia de la Cruz
Actualizaciones en Fisiopatología
Matías Maskin
Global Psoriasis Atlas (GPA) y Epidemiologia en LATAM
Chris Griffiths
Severidad en Psoriasis: Categorías
Peter van de Kerkhof
Metas de tratamiento, Target to treat
Cristina Echeverría
Discusión
Presentación de casos clínicos
Claudia de la Cruz, Cristina Echeverría, César González, Matías Maskin, Peter van de Kerkhof
2º MÓDULO
Masterclass 2021 Programa: Actualizaciones en Psoriasis
Timezones:
Guatemala City/San Jose: 12:00 pm – 2:00 pm
Bogota/Mexico City: 1:00 pm – 3:00 pm
Santiago/Asunción: 2:00 pm – 4:00 pm
Buenos Aires/São Paulo: 3:00 pm – 5:00 pm
Agenda
Actualizaciones Clínicas
Enrique Rivas
Actualizaciones en Psoriasis Ungueal y Pustulosa
César González
Actualizaciones en Comorbilidades; manifestaciones extracutáneas
Ron Vender
Actualizaciones en Artritis Psoriática
Alice Gottlieb
Discusión
Presentación de casos clínicos
Claudia de la Cruz, Cristina Echeverría, César González, Angela Londoño, Enrique Rivas, Peter van de Kerkhof
3º MÓDULO
Masterclass 2021 Programa: Actualizaciones en Psoriasis
Timezones:
Guatemala City/San Jose: 12:00 pm – 2:00 pm
Bogota/Mexico City: 1:00 pm – 3:00 pm
Santiago/Asunción: 2:00 pm – 4:00 pm
Buenos Aires/São Paulo: 3:00 pm – 5:00 pm
Agenda
Actualización en Terapias Convencionales: Tópicos
Matías Maskin
Actualización en Terapias Sistémicas Convencionales: Metotrexato (oral, inyectable), qué hay de nuevo
Angela Londoño
Actualización en Terapias Sistémicas Convencionales: Fototerapia (PUVA; NBUVB; EXCIMER), qué hay de nuevo
César González
Nuevas Terapias Orales: Apremilast, inhibidores JAK, Tyk2
Cristina Echeverría
Discusión
Presentación de casos clínicos
Claudia de la Cruz, Cristina Echeverría, César González, Angela Londoño, Matías Maskin, Peter van de Kerkhof
4º MÓDULO
Masterclass 2021 Programa: Actualizaciones en Psoriasis
Timezones:
Guatemala City/San Jose: 12:00 pm – 2:00 pm
Bogota/Mexico City: 1:00 pm – 3:00 pm
Santiago/Asunción: 2:00 pm – 4:00 pm
Buenos Aires/São Paulo: 3:00 pm – 5:00 pm
Agenda
Actualización en Terapias Biológicas: bloqueadores Anti TNF alfa
Claudia de la Cruz
Actualización en Terapias Biológicas: Biosimilares
Cristina Echeverría
Actualización en Terapias Biológicas: Inhibidores de IL17
Enrique Rivas
Inhibidores de Il12 y 23
Matías Maskin
Discusión
Presentación de casos clínicos
Claudia de la Cruz, Cristina Echeverría, César González, Angela Londoño, Matías Maskin, Enrique Rivas, Peter van de Kerkhof
5º MÓDULO
Masterclass 2021 Programa: Actualizaciones en Psoriasis
Timezones:
Guatemala City/San Jose: 12:00 pm – 2:00 pm
Bogota/Mexico City: 1:00 pm – 3:00 pm
Santiago/Asunción: 2:00 pm – 4:00 pm
Buenos Aires/São Paulo: 3:00 pm – 5:00 pm
Actualización en Terapias Biológicas: lo nuevo (inhibidores de IL36)
César González
Psoriasis y salud mental
Karina Malvido
Psoriasis y Covid I: Cómo afecta la pandemia a nuestros pacientes
Claudia de la Cruz
Psoriasis y Covid II: VACUNAS en latam
Juan Bravo Ojeda
Discusión
Mesa redonda: Cómo escoger el Tratamiento adecuado para mi paciente
Claudia de la Cruz, Cristina Echeverría, César González, Karina Malvido, Juan Bravo Ojeda
DAY 1 – FRIDAY, JANUARY 15, 2021
Epidemiology, Pathogenesis and Comorbidities
Timezones:
Agenda
OPENING COMMENTS
Mahira Hamdy El Sayed, MSc, MD
The Global Psoriasis Atlas: Epidemiology and access
Christopher EM Griffiths, OBE, MD, FRCP, FMedSci
Pathophysiology of psoriasis and implications for treatment
Mohamed El-Komy, MD
CLINICAL PRESENTATIONS OF PSORIASIS AS SYSTEMIC DISEASE
Case 1: Psoriatic Arthritis
Ahmed Nassar, Ain Shams University
Case 2: Cardiovascular
Miriam Samir, Ain Shams University
Case 3: Obesity with diabetes
Aya AlOrbani, Cairo University
CLOSING
DAY 2 – FRIDAY, JANUARY 22, 2021
Phenotypes, Disease Assessment and Treatment Targets
Timezones:
Agenda
Every patient has his own psoriasis
Peter van de Kerkhof, MD, PhD
Erythroderma – Case + Panel discussion
Mahira Hamdy El Sayed, MSc, MD
Pustular psoriasis
Nejib Doss, MD
Pediatric psoriasis
Mahira Hamdy El Sayed, MSc, MD
Audience Q & A
Faculty
DAY 3 – FRIDAY, JANUARY 29, 2021
Treatment Options and Management
Timezones:
Agenda
How to treat patients with mild disease
Mahira Hamdy El Sayed, MSc, MD
What to do when topicals are not appropriate anymore
Mohamed El-Komy, MD
How to treat patients with severe psoriasis of the skin
Peter van de Kerkhof, MD, PhD
How to treat psoriasis with comorbidities
Christopher EM Griffiths, OBE, MD, FRCP, FMedSci
Audience Q & A
Faculty
DAY 4 – FRIDAY, FEBRUARY 5, 2021
Specific Areas and Specific Situations
Timezones:
Agenda
Discussion: Biosimilars
Christopher EM Griffiths, OBE, MD, FRCP, FMedSci, moderator
Mahira Hamdy El Sayed, MSc, MD, Omid Zargari, MD, FAAD, panelists
Discussion: Psoriasis in women
Peter van de Kerkhof, MD, PhD, moderator
Mahira Hamdy El Sayed, MSc, MD, panelist
Nails and Scalp
Mohamed El-Komy, MD
Pruritis + other symptoms
Nejib Doss, MD
Audience Q & A
Faculty
DAY 5 – FRIDAY, FEBRUARY 12, 2021
Challenging Cases
Timezones:
Agenda
Challenging cases by attendees
Asma Ghanem Bashir, Libya
Moneer Omran Bugrein, Libya
Sahar Dadkhahfar, Iran
Manal Elmubarak, Sudan
Mostafa Khalaf, Egypt
Alia Ramadan, Egypt
The future of psoriasis
Peter van de Kerkhof, MD, PhD
Personalized medicine
Christopher EM Griffiths, OBE, MD, FRCP, FMedSci
Key learnings and program closing
Mahira Hamdy El Sayed, MSc, MD, moderator
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.